TY - JOUR
T1 - Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C
T2 - A randomized, controlled study
AU - Bruno, R.
AU - Sacchi, P.
AU - Scagnolari, C.
AU - Torriani, F.
AU - Maiocchi, L.
AU - Patruno, S.
AU - Bellomi, F.
AU - Filice, G.
AU - Antonelli, G.
PY - 2007/8
Y1 - 2007/8
N2 - Background: Peginterferon alfa-2a and alfa-2b, the two commercially available pegylated interferons, have different pharmacokinetic properties that produce differing abilities to suppress replication of the hepatitis C virus. Aim: To compare the pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naive patients with chronic hepatitis C. Methods: Patients were randomized to receive peginterferon alfa-2a, 180 μg (n = 10) or peginterferon alfa-2b 1.0 μg/kg (n = 12) once weekly. The enzymatic activity of 2′5′-oligoadenylate synthetase and levels of neopterin and β2-microglobulin were measured at baseline and at 24, 48, 120 and 168 h. Results: Oligoadenylate synthetase activity and serum neopterin and β2-microglobulin concentrations did not differ significantly between the two patient groups at any time point, nor was there a significant correlation between the serum area under the concentration-time curve of either peginterferon and the area under the concentration-time curve for 2′,5′-oligoadenylate synthetase, neopterin and β2- microglobulin. The area under the concentration-time curves calculated for these three markers did not correlate with body mass index stratified at 2 for either peginterferon. Conclusions: Despite pharmacokinetic differences between peginterferon alfa-2a and peginterferon alfa-2b, the pharmacodynamic profiles of the two formulations appear to be comparable.
AB - Background: Peginterferon alfa-2a and alfa-2b, the two commercially available pegylated interferons, have different pharmacokinetic properties that produce differing abilities to suppress replication of the hepatitis C virus. Aim: To compare the pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naive patients with chronic hepatitis C. Methods: Patients were randomized to receive peginterferon alfa-2a, 180 μg (n = 10) or peginterferon alfa-2b 1.0 μg/kg (n = 12) once weekly. The enzymatic activity of 2′5′-oligoadenylate synthetase and levels of neopterin and β2-microglobulin were measured at baseline and at 24, 48, 120 and 168 h. Results: Oligoadenylate synthetase activity and serum neopterin and β2-microglobulin concentrations did not differ significantly between the two patient groups at any time point, nor was there a significant correlation between the serum area under the concentration-time curve of either peginterferon and the area under the concentration-time curve for 2′,5′-oligoadenylate synthetase, neopterin and β2- microglobulin. The area under the concentration-time curves calculated for these three markers did not correlate with body mass index stratified at 2 for either peginterferon. Conclusions: Despite pharmacokinetic differences between peginterferon alfa-2a and peginterferon alfa-2b, the pharmacodynamic profiles of the two formulations appear to be comparable.
UR - http://www.scopus.com/inward/record.url?scp=34447298143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447298143&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2007.03392.x
DO - 10.1111/j.1365-2036.2007.03392.x
M3 - Article
C2 - 17635371
AN - SCOPUS:34447298143
VL - 26
SP - 369
EP - 376
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 3
ER -